Sharemaestro Newsreel

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer PFE announced that the FDA has accepted the supplemental new drug application (sNDA) for Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), for an expanded use in prostate cancer. The sNDA is seeking approval …

EU Okays AstraZeneca’s Etcamah As US Wait Continues

The European Union has approved AstraZeneca's drug Etcamah. This approval comes as the United States' decision on the drug is still pending. The article highlights this significant regulatory milestone for AstraZeneca.

Lilly to file for next-gen obesity drug approval in early 2027

Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and …

How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly's nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo's Wegovy and Ozempic. The case …

Lilly Endowment reports 90.4M Eli Lilly (LLY) shares, a 9.6% stake

Lilly Endowment, Inc. has reported beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock, representing a 9.6% stake as of June 30, 2026. This ownership, based on 941,741,406 total shares outstanding, grants Lilly Endowment sole voting and dispositive power over its …

Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access

Arkansas is suing 13 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Eli Lilly & Co., alleging they imposed unlawful restrictions on healthcare providers seeking drug discounts under the federal 340B Drug Pricing Program. Attorney General Tim Griffin claims these companies, along with their …

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

Bristol Myers Squibb (BMY) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2026, with Wall Street anticipating $1.59 EPS on $11.67 billion in revenue. The company has a Zacks Earnings ESP of +0.51% and a …

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials for its experimental obesity drug, retatrutide, and plans to submit an FDA application in Q1 2027. The drug showed significant weight loss in patients with severe obesity and cardiovascular disease (22.6%) and in …

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

MCLEAN, Va., July 23, 2026--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer …

FDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’

The FDA has approved Johnson & Johnson's Ottava Robotic Surgical System for several soft tissue surgeries, enabling J&J to compete with established players like Intuitive Surgical and Medtronic. J&J plans a limited commercial launch in the U.S. initially, focusing on customer success before expanding …

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Eli Lilly announced plans to file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, following successful results in two more late-stage trials. The drug demonstrated significant weight loss and improved blood sugar levels in adults with obesity, including …

Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data

Eli Lilly is preparing to submit applications for its new weight-loss drug, retatrutide, following successful Phase 3 trial results. These trials showed significant body weight reduction in overweight or obese patients with type 2 diabetes. Patients lost an average of nearly 13% of their …

Etcamah approval: AstraZeneca (NASDAQ: AZN) wins EU OK in HR+ breast cancer

AstraZeneca's Etcamah (camizestrant), combined with a CDK4/6 inhibitor, has received EU approval for the 1st-line treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer demonstrating an emergent ESR1 mutation and no disease progression on endocrine therapy. This approval is based …

Earnings Preview: Grifols to Report Financial Results on July 28

Grifols is scheduled to report its financial results on July 28. Investors and analysts will be closely watching the report for insights into the company's performance.

NOVARTIS AG : Jefferies gives a Neutral rating

Jefferies analyst Michael Leuchten has maintained a Neutral rating on Novartis AG (NOVN) stock, keeping the target price unchanged at CHF 110. This announcement comes amidst other recent analyst ratings for Novartis, including Neutral ratings from DZ Bank and Bernstein, and Buy ratings from …

Johnson & Johnson $JNJ Stake Lessened by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its stake in Johnson & Johnson by 3.9% in the first quarter, selling over 232,000 shares. Despite this, J&J accounts for a significant portion of PNC's portfolio, valued at over $1.41 billion. The pharmaceutical giant recently received FDA …

GSK: Glaxosmithkline plc - ADR Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock price, analysis, news, and trading ideas for Glaxosmithkline plc (GSK) ADR. It includes current market data, financial fundamentals such as market cap, PE ratio, and EPS, and recent news headlines related to GSK's drug approvals and developments. The …

Sanofi’s New CEO Has A Simple To-Do List: Deals Or Buybacks

Berenberg, an investment bank, suggests Sanofi's CEO Belén Garijo needs to either pursue acquisitions to drive growth and close a "deep" valuation gap or implement a EUR5 billion share buyback program that could boost earnings per share by about 5%. The bank emphasizes the …

Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality

At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB)

Biogen recently received US FDA approval for its at-home LEQEMBI IQLIK autoinjector for early Alzheimer's treatment and reported positive Phase 2 CELIA data for diranersen, showing tau reduction. These developments suggest Biogen is a key player in Alzheimer's treatment, expanding options for both amyloid …

REG - AstraZeneca PLC - Etcamah approved in the EU for ER+ breast cancer

AstraZeneca's Etcamah (camizestrant), in combination with a CDK4/6 inhibitor, has received approval in the EU for treating adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation. This approval, based on the SERENA-6 Phase III trial, demonstrated a 56% …

Sanofi Elevates Top US Atty To General Counsel

French pharmaceutical company Sanofi SA announced the promotion of its North American general counsel to group general counsel. This change follows the departure of the current legal chief after four years in the role. The article, however, does not provide the name of the …

Grifols stock trades steady as debt reduction and margin recovery shape investor focus

Grifols stock is holding steady as the Spanish plasma specialist focuses on debt reduction and margin recovery. Recent quarterly figures show improved adjusted earnings, higher operating margins, and a reduction in net debt, driven by better utilization of plasma centers and cost discipline. The …

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

In the latest close session, Novo Nordisk (NVO) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%. The drugmaker's shares have seen an …

FDA issues untitled letters to Sanofi and Viatris for false advertising

The FDA's Office of Prescription Drug Promotion has sent untitled letters to Sanofi and Viatris for making misleading claims in their product promotions. Sanofi was cited for an email promoting Beyfortus, which incorrectly suggested it prevents general RSV, while Viatris was reprimanded for a …

Novo Nordisk sues rival Eli Lilly over ‘misleading' weight-loss drug advertising

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the rival pharmaceutical company of false advertising regarding its weight-loss drugs Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly's advertising campaigns rely on outdated studies, comparing their highest doses with lower doses of Novo …

FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use

Pfizer Inc. announced that the FDA has accepted its supplemental New Drug Application for a Priority Review of TALZENNA in combination with XTANDI for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer. The FDA's Prescription Drug User Fee Act action date is …

How AI is Reshaping the Patient Care Journey

Sanofi is leveraging Digital and AI technologies to transform the patient care journey, addressing fragmentation from diagnosis to long-term treatment. Their approach spans pre-prescription (identification and diagnosis) and post-prescription (onboarding and support) phases. By integrating AI-driven tools like AccelRare, FabryFind, iCare+, and Companion App, …

Scilex Sells Vivasor Preferred Shares Back for $12.0 Million, Paid in Tranches Through 2027

Scilex (SCLX) has entered into a stock repurchase agreement to sell its previously acquired Vivasor preferred shares back to Vivasor for approximately $12.0 million. The payment will be made in five tranches from July 18, 2026, through June 30, 2027. This transaction aims to …

GSK (GSK) Q4 2024 earnings summary

GSK announced strong Q4 2024 results with 8% sales growth to over GBP 31.4 billion, driven by specialty medicines and vaccines. Core operating profit increased by 13%, and core EPS rose by 12% to 159.3p, leading to a dividend increase and a new GBP …

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new …

DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal

The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …

Pfizer's prostate cancer drug combination gets US FDA priority review

Pfizer announced that the U.S. Food and Drug Administration has granted priority review for an expanded approval of its prostate cancer drug combination, Talzenna and Xtandi. This combination targets men with metastatic castration-sensitive prostate cancer who have HRR mutations. The FDA is expected to …

US Judge Casts Doubt on 69,000 Cases Alleging J&J Talc Caused Cancer

A federal judge has questioned the validity of approximately 69,000 lawsuits claiming Johnson & Johnson's talc products caused ovarian cancer, demanding plaintiffs provide more specific evidence. U.S. Magistrate Judge Rukhsanah Singh expressed doubt after expert testimony indicated an inability to definitively link talcum powder …

Pfizer trial: TALZENNA combo cut progression-or-death risk 52%

Pfizer announced that the FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The sNDA is supported by Phase 3 TALAPRO-3 trial data showing the …

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations NEW YORK, July …